Filtern
Dokumenttyp
Sprache
- Englisch (3)
Referierte Publikation
- ja (3)
Schlagworte
- Acrylic acid (1)
- Dangerous goods (1)
- Decachlorotetrasilane (1)
- False-positive results (1)
- Finite element method (1)
- Hexachlorodisilane (1)
- Mass-Spectrometry (1)
- Octachlortrisilane (1)
- Polychlorosilanes (1)
- Railway transport (1)
Organisationseinheit der BAM
Experiments according to a test specified in the UN Recommendations on the Transport of Dangerous Goods, Manual of Tests and Criteria, and numerical simulations by means of a finite element method are employed to determine the self-accelerating decomposition temperature of acrylic acid in a railroad tank car. The results demonstrate that the transport of acrylic acid in big tank cars is safe as long as some basic conditions are taken into account.
According to UN Test O.2, surprisingly, the polychlorosilanes hexachlorodisilane (HCDS), octachlorotrisilane (OCTS) and decachlorotetrasilane (DCTS) formally fulfill the criteria of the “test for oxidizing liquids”. This result is in contrast to the properties of polychlorosilanes that are described in the literature and those we have experienced in our own production.
By investigating the reaction products from the UN O.2 test reactor, using IR, Raman and XPS spectroscopy, it was shown that the results are not due to oxidizing properties of HCDS, OCTS or DCTS, but are caused by the specified test substance cellulose. To our knowledge, this is the very first substance class in which the reference substance oxidizes the test sample, instead of vice versa. This represents an important limitation of the internationally used UN Test O.2 for this substance class. The cause for this false-positive result is the known high degree of affinity of oxygen to silicon.
It is shown that the correctly executed UN Test O.2 produces false-positive results and that the polychlorosilanes do not have an oxidizing effect and, therefore, do not have to be classified as “oxidizing substances”.
Limited data exist on the pharmacokinetic profile of novel direct acting antivirals in kidney transplant recipients. Daclatasvir is primarily eliminated via the biliary route and sofosbuvir via the renal route; here we report the pharmacokinetic profile of combined treatment with these compounds in a prospective study of hepatitis C virus positive kidney transplant recipients (EudraCT: 2014-004551-32). In this study plasma samples of 16 HCV positive kidney transplant recipients receiving daclatasvir and sofosbuvir were collected at 4 time points at day 1, 7, 14, 21, 56, and 84 after start of treatment. Inclusion criteria were stable graft function and an estimated GFR (eGFR) > 30mL/min/1.73m. Daclatasvir, sofosbuvir and GS-331007 (inactive metabolite of sofosbuvir) plasma concentrations were determined using ultra-performance liquid chromatography quadrupole time of flight mass spectrometry. All patients showed a rapid virological response with HCV RNA below the detection limit 21 days after the start of therapy (medium time to viral clearance). No difference of the areas under the concentration-time curve (AUC) of daclatsavir, sofosbuvir and GS-331007 was observed between patients with an eGFR below or ≥ 60mL/min. For GS-331007, no relevant changes of trough levels were observed over time. Mean GS-331007 trough levels were 339.5±174.9 ng/mL in patients with an eGFR ≥ 60mL/min and 404.3±226 ng/mL in patients with an eGFR < 60mL/min at day 7 (p=0.52). At day 84, GS-331007 trough levels were 357.8±200.8 ng/mL and 404.2±70.2 ng/mL in patients with an eGFR ≥ 60 mL/min and in patients with an eGFR < 60 mL/min, respectively (p=0.51). The accumulation ratios of renally eliminated GS-331007 for AUC and Cmax did not significantly differ between the two eGFR groups at day 7. An impaired eGFR (30-60 mL/min) does not lead to a dose accumulation of daclatasvir, sofosbuvir and GS-331007. This study provides the rationale for future studies investigating the pharmacokinetic profile of sofosbuvir based HCV treatment in kidney transplant recipients with an eGFR < 30 mL/min.